Epidemiologic Approaches to the Study of Parkinson??s Disease Etiology, Epidemiology, vol.10, issue.3, pp.327-336, 1999. ,
DOI : 10.1097/00001648-199905000-00023
The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it, Annals of Neurology, vol.43, issue.6, pp.804-812, 1992. ,
DOI : 10.1002/ana.410320616
Oxidation reactions in Parkinson's disease, Neurology, vol.40, pp.32-37, 1990. ,
DOI : 10.1002/ana.24011
Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients, Neurology, vol.58, issue.12, pp.1809-1815, 2002. ,
DOI : 10.1212/WNL.58.12.1809
Oxy-radicals and cancer, The Lancet, vol.344, issue.8926, pp.862-863, 1994. ,
DOI : 10.1016/S0140-6736(94)92832-0
Gene, New England Journal of Medicine, vol.342, issue.21, pp.1560-1567, 2000. ,
DOI : 10.1056/NEJM200005253422103
Functional association of the parkin gene promoter with idiopathic Parkinson's disease, Human Molecular Genetics, vol.11, issue.22, pp.2787-2792, 2002. ,
DOI : 10.1093/hmg/11.22.2787
Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27, Proceedings of the National Academy of Sciences, vol.100, issue.10, pp.5956-5961, 2003. ,
DOI : 10.1073/pnas.0931262100
Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer, Genes, Chromosomes and Cancer, vol.97, issue.1, pp.40-52, 2003. ,
DOI : 10.1002/gcc.10236
The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor, Nature Medicine, vol.7, issue.5, pp.569-574, 2001. ,
DOI : 10.1038/87895
Levodopa Therapy and the Risk of Malignant Melanoma, Annals of Pharmacotherapy, vol.15, issue.3, pp.382-385, 2000. ,
DOI : 10.1345/aph.19150
Genetic polymorphisms in Parkinson's disease, Neurotoxicology, vol.19, pp.635-644, 1998. ,
Metabolic Polymorphisms and Cancer Susceptibility, IARC Scientific Publications Lyon: International Agency for Research on Cancer, issue.148, pp.209-229, 1999. ,
DOI : 10.1007/3-540-30683-8_1053
Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: An exploratory case-control study, Movement Disorders, vol.64, issue.5, pp.830-837, 2001. ,
DOI : 10.1002/mds.1170
Failure of the ubiquitin???proteasome system in Parkinson's disease, Nature Reviews Neuroscience, vol.275, issue.8, pp.589-594, 2001. ,
DOI : 10.1038/35086067
The Proteasome ??? An Emerging Therapeutic Target in Cancer, New England Journal of Medicine, vol.348, issue.26, pp.2597-2598, 2003. ,
DOI : 10.1056/NEJMp030092
CANCER AS A CAUSE OF DEATH AMONG PATIENTS WITH OTHER CHRONIC DISEASES, Journal of the American Medical Association, vol.162, issue.10, p.1003, 1956. ,
DOI : 10.1001/jama.1956.02970270063024
Parkinsonism and cancer, Union Med Can, vol.92, pp.169-174, 1963. ,
Parkinsonism: onset, progression, and mortality, Neurology, vol.17, issue.5, pp.427-442, 1967. ,
DOI : 10.1212/WNL.17.5.427
Prevalence of neoplasms and causes of death in paralysis agitans A necropsy study, Neurology, vol.23, issue.3, pp.215-222, 1973. ,
DOI : 10.1212/WNL.23.3.215
Epidemiology of Parkinson's Disease in a Japanese City, Archives of Neurology, vol.40, issue.3, pp.151-154, 1983. ,
DOI : 10.1001/archneur.1983.04050030045008
Low cancer rates among patients with Parkinson's disease, Annals of Neurology, vol.162, issue.5, pp.505-509, 1985. ,
DOI : 10.1002/ana.410170514
A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson's disease, Neurology, vol.37, issue.2, pp.226-232, 1987. ,
DOI : 10.1212/WNL.37.2.226
Parkinson's disease and its comorbid disorders: An analysis of Michigan mortality data, 1970 to 1990, Neurology, vol.44, issue.10, pp.1865-1868, 1970. ,
DOI : 10.1212/WNL.44.10.1865
Occurrence of different cancers in patients with Parkinson's disease, BMJ, vol.310, issue.6993, pp.1500-1501, 1995. ,
DOI : 10.1136/bmj.310.6993.1500
Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology?, Journal of Neurology, Neurosurgery & Psychiatry, vol.58, issue.3, pp.293-299, 1995. ,
DOI : 10.1136/jnnp.58.3.293
Mortality in a population-based cohort of patients treated with antiparkinsonian drugs, Acta Neurologica Scandinavica, vol.79, issue.1, pp.20-26, 1998. ,
DOI : 10.1111/j.1600-0404.1998.tb00604.x
Mortality cancer risk in parkinsonian patients: A population-based study, Neurology, vol.52, issue.2, pp.395-398, 1999. ,
DOI : 10.1212/WNL.52.2.395
Mortality and cancer incidence in patients with Parkinson's disease, Journal of Neurology, vol.247, issue.6, pp.429-434, 2000. ,
DOI : 10.1007/s004150070171
Nonfatal Cancer Preceding Parkinson???s Disease: A Case-Control Study, Epidemiology, vol.13, issue.2, pp.157-164, 2002. ,
DOI : 10.1097/00001648-200203000-00010
Statistical methods in cancer research The design and analysis of cohort studies, IARC Scientific Publications No. Lyon: International Agency for Research on Cancer, vol.2, issue.82, 1987. ,
History of the Rochester Epidemiology Project, Mayo Clinic Proceedings, vol.71, issue.3, pp.266-274, 1996. ,
DOI : 10.4065/71.3.266
Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990, Neurology, vol.52, issue.6, pp.1214-1220, 1976. ,
DOI : 10.1212/WNL.52.6.1214
Survival Study of Parkinson Disease in Olmsted County, Minnesota, Archives of Neurology, vol.60, issue.1, pp.91-96, 2003. ,
DOI : 10.1001/archneur.60.1.91
Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project, Neurology, vol.43, issue.10, pp.1918-1926, 1993. ,
DOI : 10.1212/WNL.43.10.1918
Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale, Am J Epidemiol, vol.145, pp.72-80, 1997. ,
Modeling survival data: extending the Cox model, 2000. ,
DOI : 10.1007/978-1-4757-3294-8
Cigarette smoking as a cause of cancer, Cancer rates and risks. NIH Publication No. 96-691. Bethesda, Maryland: National Cancer Institute, pp.67-72, 1996. ,
Latency Analysis in Occupational Epidemiology, Archives of Environmental Health: An International Journal, vol.106, issue.2, pp.95-100, 1990. ,
DOI : 10.1002/1097-0142(19801215)46:12<2736::AID-CNCR2820461233>3.0.CO;2-L
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET, Journal of Neurology, Neurosurgery & Psychiatry, vol.64, issue.3, pp.314-319, 1998. ,
DOI : 10.1136/jnnp.64.3.314
Clinical epidemiology: The architecture of clinical research, Statistics in Medicine, vol.117, issue.11, 1985. ,
DOI : 10.1002/sim.4780141110
Medical Services Utilization and Prognosis in Parkinson Disease: A Population-Based Study, Mayo Clinic Proceedings, vol.77, issue.9, pp.918-925, 2002. ,
DOI : 10.1016/S0025-6196(11)62259-3
Skin pigmentation and risk of Parkinson's disease (PD), Neurology, vol.52, p.540, 1999. ,
SKIN COLOUR, MPTP, AND PARKINSON'S DISEASE, The Lancet, vol.330, issue.8552, p.212, 1987. ,
DOI : 10.1016/S0140-6736(87)90786-0
The epidemiology of skin cancer, British Journal of Dermatology, vol.50, issue.s61, pp.1-6, 2002. ,
DOI : 10.1023/A:1008980919928